2010
DOI: 10.1016/j.clindermatol.2009.03.005
|View full text |Cite
|
Sign up to set email alerts
|

The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
52
0
12

Year Published

2011
2011
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 77 publications
(64 citation statements)
references
References 77 publications
0
52
0
12
Order By: Relevance
“…Furthermore, it is already in use in many countries in clinical practice without any significant side effects (Sativex) (16). This is especially promising, because the currently available, most effective anti-acne agent, isotretinoin, is known to cause serious side effects (2,69,70). These data, together with our current findings, point to a promising, costeffective, and, likely, well-tolerated new strategy for treating acne vulgaris, the most common human skin disease.…”
Section: Discussionmentioning
confidence: 52%
“…Furthermore, it is already in use in many countries in clinical practice without any significant side effects (Sativex) (16). This is especially promising, because the currently available, most effective anti-acne agent, isotretinoin, is known to cause serious side effects (2,69,70). These data, together with our current findings, point to a promising, costeffective, and, likely, well-tolerated new strategy for treating acne vulgaris, the most common human skin disease.…”
Section: Discussionmentioning
confidence: 52%
“…Isotretinoin leads to sebaceous gland atrophy through inhibiting basal sebocyte proliferation, and decreases the release of pro-inflammatory mediators through reduction of neutrophil migration and P. acnes population. [171827] Because beta-defensin release was influenced by pro-inflammatory cytokines, isotretinoin could be effective in the release of hBD through all of these abovementioned mechanisms. Harder et al .…”
Section: Discussionmentioning
confidence: 99%
“…In addition, delivery of retinoids is relatively inefficient as distribution is restricted by their high lipophilicity and limited absorption from oral administration. Consequently, the dose of a 13cRA regimen is relatively high (40-80 mg/day; Rigopoulos et al 2010); there are promising innovations in drug delivery methods, such as cyclodextrins, to improve the plasma concentrations of smaller doses of 13cRA (Lin et al 2007, Trichard et al 2007.…”
Section: Discussionmentioning
confidence: 99%